ArticleJournal of managed care & specialty pharmacy2021
A RESPONSE TO: "COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES".
Ciaran N Kohli-Lynch et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.